Loading...
ESMO congress Lung Cancer 20172025-01-28T17:05:36+01:00

ESMO 2017 – Madrid

 

Lecture Board: David R. Gandara, MD; Nicolas Girard, MD, PhD; Maximilian Hochmair, MD; Silvia Novello, MD, PhD; Michael Thomas, MD; Gérard Zalcman, MD
Medical Writer: Judith Moser, MD

DOWNLOADS

All downloads from ESMO 2017

ESMO 2020 Lung Cancer English

Full report (english)

ESMO 2017 Mandarin

Full report (mandarin)

ESMO 2017 Japanese

Full report (japanese)

EXPERT VIDEOS

All videointerviews from ESMO 2017

Hossein Borghaei discusses the latest immunotherapeutic treatment options to emerge for lung cancer at the 2017 ESMO congress.

Nicolas Girard on the sequencing of targeted agents against EGFR positive NSCLC, and further considerations for treatment of the disease including side effects and possible combination therapies.

Lecia Sequist on how best to treat oncogene-driven oligometastatic lung cancer, given progression through multiple lines of treatment.

Filippo de Marinis on the latest data from the OAK trial studying the PD-L1 antibody atezolizumab that was presented at the 2017 ESMO congress, including efficacy within particular patient subgroups, and tolerability.

In the area of targeted therapies, the debate on sequencing of drugs is gaining momentum, as head-to-head comparisons have shown superiority of potent later-generation drugs over established first-line compounds. This is true for the EGFR tyrosine kinase inhibitor osimertinib, which outperformed gefitinib and erlotinib in EGFR-mutant lung cancer, as well as for the ALK inhibitor alectinib that gave rise to improvements in progression-free survival and central nervous system outcomes when compared to crizotinib in the ALK-positive setting.

David R. Gandara • MD, Professor of Medicine UC Davis Comprehensive Cancer Center Sacramento, California, USA
Go to Top